二甲双胍对无糖尿病冠心病患者左心室肥厚的随机对照试验:MET-REMODEL研究
MET-REMODEL试验将68例无糖尿病但伴胰岛素抵抗和/或糖尿病前期的冠心病患者随机分配至二甲双胍XL(每日2000 mg)组或安慰剂组治疗12个月。改良意向性分析(n=63)显示,二甲双胍组左心室质量指数(LVMI)较安慰剂组显著降低,绝对平均差为-1.37(95%CI:-2.63至-0.12,P=0.033)。二甲双胍还显著降低了左心室质量、体重、皮下脂肪组织、诊室收缩压及氧化应激标志物,但糖化血红蛋白和空腹胰岛素抵抗指数组间无差异。
要点
- 二甲双胍可显著降低无糖尿病冠心病患者的LVMI(绝对平均差-1.37,P=0.033)。
- 二甲双胍还降低左心室质量、体重、皮下脂肪、诊室收缩压及氧化应激标志物。
- 糖化血红蛋白和空腹胰岛素抵抗指数组间无显著差异,LVH为替代终点需大型结局试验验证。
核心结论
- 二甲双胍治疗显著降低无糖尿病冠心病患者的LVMI、左心室质量、诊室收缩压、体重及氧化应激。
- LVH是心血管结局的良好替代标志物,但二甲双胍的心脏保护作用仍需大型心血管结局试验证实。
研究设计与样本
- 随机对照试验,纳入68例无糖尿病但伴胰岛素抵抗和/或糖尿病前期的冠心病患者,随机接受二甲双胍XL(每日2000 mg)或安慰剂治疗12个月。
- 主要终点为磁共振成像评估的左心室质量指数(LVMI,按身高1.7次方指数化)。
- 改良意向性分析纳入63例患者。
主要发现
- 二甲双胍组LVMI较安慰剂组显著降低,绝对平均差-1.37(95%CI:-2.63至-0.12,P=0.033)。
- 二甲双胍还显著降低左心室质量(P=0.032)、体重(P=0.001)、皮下脂肪组织(P=0.024)、诊室收缩压(P=0.022)及硫代巴比妥酸反应物质浓度(氧化应激生物标志物,P=0.04)。
- 研究结束时糖化血红蛋白A1C浓度和空腹胰岛素抵抗指数组间无差异。
临床怎么用
- 对于无糖尿病但伴胰岛素抵抗和/或糖尿病前期的冠心病患者,二甲双胍可能有助于降低LVMI、体重、收缩压及氧化应激。
- 二甲双胍的心脏保护作用尚未确立,不能仅基于LVH替代终点推荐用于心血管预防。
局限性
- 样本量较小(随机68例,分析63例),需大型心血管结局试验验证二甲双胍的心脏保护作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: We tested the hypothesis that metformin may regress left ventricular hypertrophy (LVH) in patients who have coronary artery disease (CAD), with insulin resistance (IR) and/or pre-diabetes. METHODS AND RESULTS: We randomly assigned 68 patients (mean age 65 ± 8 years) without diabetes who have CAD with IR and/or pre-diabetes to receive either metformin XL (2000 mg daily dose) or placebo for 12 months. Primary endpoint was change in left ventricular mass indexed to height1.7 (LVMI), assessed by magnetic resonance imaging. In the modified intention-to-treat analysis (n = 63), metformin treatment significantly reduced LVMI compared with placebo group (absolute mean difference -1.37 (95% confidence interval: -2.63 to -0.12, P = 0.033). Metformin also significantly reduced other secondary study endpoints such as: LVM (P = 0.032), body weight (P = 0.001), subcutaneous adipose tissue (P = 0.024), office systolic blood pressure (BP, P = 0.022) and concentration of thiobarbituric acid reactive substances, a biomarker for oxidative stress (P = 0.04). The glycated haemoglobin A1C concentration and fasting IR index did not differ between study groups at the end of the study. CONCLUSION: Metformin treatment significantly reduced LVMI, LVM, office systolic BP, body weight, and oxidative stress. Although LVH is a good surrogate marker of cardiovascular (CV) outcome, conclusive evidence for the cardio-protective role of metformin is required from large CV outcomes trials.
引用
- Mohan M, Al-Talabany S, McKinnie A, et al. A randomized controlled trial of metformin on left ventricular hypertrophy in patients with coronary artery disease without diabetes: the MET-REMODEL trial. Eur Heart J. 2019. PMID: 30993313. doi:10.1093/eurheartj/ehz203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。